Art. -Nr.: HY-10129

Veliparib

Name: Veliparib
Brand: MedChemExpress
SKU: HY-10129
Price: 66.00 USD
Availability: InStock
Rating: 5 (51 reviews)

(Synonyms: ABT-888)

51 Cited Publications

Kundenbewertung

Based on 51 publication(s) in Google Scholar

Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with K_is of 5.2 and 2.9 nM, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.77%
CAS. Nr.: 912444-00-9
Formel: C₁₃H₁₆N₄O
Molecular Weight:244.29

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Veliparib Chemical Structure

CAS. Nr.: 912444-00-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (51)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with K_is of 5.2 and 2.9 nM, respectively^[1].

IC₅₀ & Target^[1]

PARP-2

2.9 nM (Ki)

PARP-1

5.2 nM (Ki)

Autophagy

Alle PARP Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	133.5 μM Compound: ABT-888	Inhibition of PARP1 in human A549 cells assessed as potentiation of TMZ-mediated cytotoxicity by measuring TMZ IC50 for growth inhibition at 0.5 uM by SRB assay (Rvb TMZ IC50 = 295 uM) Inhibition of PARP1 in human A549 cells assessed as potentiation of TMZ-mediated cytotoxicity by measuring TMZ IC50 for growth inhibition at 0.5 uM by SRB assay (Rvb TMZ IC50 = 295 uM)	[PMID: 27353531]
A549	IC₅₀	15.22 μM Compound: ABT-888	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
A549	IC₅₀	>10 μM Compound: VI	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
CAPAN-1	IC₅₀	39.7 μM Compound: ABT-888	Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay	[PMID: 24398383]
CAPAN-1	EC₅₀	>10000 nM Compound: 1; ABT-888	Cytotoxicity against BRCA2-deficient human Capan1 cells Cytotoxicity against BRCA2-deficient human Capan1 cells	[PMID: 26652717]
DLD-1	IC₅₀	0.75 μM Compound: 5	Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days	[PMID: 34570508]
DLD-1	IC₅₀	69 μM Compound: Veliparib	Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis	[PMID: 37484567]
DLD-1	IC₅₀	8.85 μM Compound: Veliparib	Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis	[PMID: 37484567]
FaDu	IC₅₀	>10 μM Compound: VI	Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
HCC1937	IC₅₀	97.16 μM Compound: ABT-888	Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay	[PMID: 24398383]
HCT-116	IC₅₀	64 μM Compound: ABT-888	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 27353531]
HeLa	IC₅₀	18.11 μM Compound: ABT-888	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
HepG2	IC₅₀	13.69 μM Compound: ABT-888	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
HGC-27	IC₅₀	16.03 μM Compound: ABT-888	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
HH	IC₅₀	>10 μM Compound: VI	Antiproliferative activity against human HH cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HH cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
HL-60	IC₅₀	>10 μM Compound: VI	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
HUVEC	IC₅₀	>100 μM Compound: Veliparib	Inhibition of cell proliferation in HUVECs Inhibition of cell proliferation in HUVECs	[PMID: 38678823]
Jurkat	EC₅₀	160 μM Compound: ABT-888	Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay	[PMID: 23850199]
Jurkat	EC₅₀	3 μM Compound: ABT-888	Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide	[PMID: 23850199]
K562	IC₅₀	>10 μM Compound: VI	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
LoVo	EC₅₀	5.94 nM Compound: 1; ABT-888	Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay	[PMID: 26652717]
LoVo	GI₅₀	6203 nM Compound: 1; ABT-888	Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay	[PMID: 26652717]
MCF7	IC₅₀	>100 μM Compound: Veliparib	Inhibition of cell proliferation in human MCF7 cells Inhibition of cell proliferation in human MCF7 cells	[PMID: 38678823]
MDA-MB-231	IC₅₀	>10 μM Compound: VI	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
MDA-MB-436	IC₅₀	>100 μM Compound: Veliparib	Inhibition of cell proliferation in human MDA-MB-436 cells assessed as PARP trapping effect Inhibition of cell proliferation in human MDA-MB-436 cells assessed as PARP trapping effect	[PMID: 38678823]
MDA-MB-468	EC₅₀	43 μM Compound: Veliparib	Growth inhibition of human MDA-MB-468 cells after 72 hrs by SRB assay Growth inhibition of human MDA-MB-468 cells after 72 hrs by SRB assay	[PMID: 27561983]
MOLT-4	IC₅₀	>10 μM Compound: VI	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
MRC5	EC₅₀	>10 μM Compound: 1; ABT-888	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 26652717]
PC-3	IC₅₀	>10 μM Compound: VI	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
Sf9	IC₅₀	<10 nM Compound: Vel	Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay	[PMID: 31042381]
Sf9	IC₅₀	1.5 nM Compound: Vel	Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay	[PMID: 31042381]
SiHa	IC₅₀	>10 μM Compound: VI	Antiproliferative activity against human SiHa cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human SiHa cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
SW-620	EC₅₀	27.1 μM Compound: Veliparib	Growth inhibition of human SW620 cells after 72 hrs by SRB assay Growth inhibition of human SW620 cells after 72 hrs by SRB assay	[PMID: 27561983]

In Vitro

Veliparib (ABT-888) is also tested against SIRT2, an enzyme that also uses NAD⁺ for catalysis, and found to be inactive (>5,000 nM). The receptor profile of Veliparib is determined in a panel of 74 receptor-binding assays at a concentration of 10 μM. Veliparib displaces control-specific binding at 50% or greater at the human H₁(61%), the human 5-HT_1A (91%), and the human 5-HT₇ (84%) sites only. The IC₅₀s for these three receptors are 5.3, 1.5, and 1.2 μM, respectively^[1].
c-Met knockdown cells show 4.2- (shMet-A; 95% CI=4-4.5) or 4.6-fold (shMet-B; 95% CI=4.4-4.8) growth inhibition when treated with 60 μM Veliparib (ABT-888). When treated with 38 μM Veliparib, c-Met knockdown cells show 2- (shMet-A; 95% CI=1.5-2.5) or 1.9-fold (shMet-B; 95% CI=1.3-2.5) growth inhibition^[2].
In HaCaT cells, at 6 h post-treatment by Veliparib (ABT-888), cell viability is significantly increases under 1,000 μM sulfur mustard (SM) exposure, whereas Veliparib does not protect cell viability under 100 μM SM exposure. Moreover, the addition of Veliparib no longer shows the protective effect at 24 h post SM exposure^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Veliparib (ABT-888) is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier in syngeneic and xenograft tumor models^[1]. In MDA-MB-231 xenograft tumor models, combination treatment (AG014699/PF-02341066 and Veliparib (ABT-888)/Foretinib) substantially reduced tumor growth compared to either inhibitor alone^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 912444-00-9
Appearance Solid
Molecular Weight 244.29
Formel C₁₃H₁₆N₄O
Color White to off-white
SMILES

O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N
Synonyms

ABT-888
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (51)

All Cell Proliferation/Viability AssayWBRT-PCRBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nature

NASP modulates histone turnover to drive PARP inhibitor resistance. [Abstract]

2025 Sep;645(8082):1071-1080. PMID: 40804522
Cancer Discov

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. [Abstract]

2017 Sep;7(9):984-998. PMID: 28588062
Cancer Res

SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer. [Abstract]

2025 May 14. PMID: 40366633
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

Nuclear ADP-ribosylation drives IFNγ-dependent STAT1α enhancer formation in macrophages. [Abstract]

2021 Jun 24;12(1):3931. PMID: 34168143

Veliparib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]

Veliparib (10 μM; 24 h). Immunoblots for STAT1a S727p in iBMDMs treated with IFNγ ± Veliparib (Vel.) as indicated.

Veliparib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]

Veliparib (10 μM; 24 h). Bar graphs showing the relative mRNA levels upon treatment IFNγ treatment ± Veliparib (Vel.).

Veliparib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]

Veliparib (10 μM; 24 h). PARP catalytic inhibition results in attenuation of NOS activity in iBMDMs. The cells were treated with IFNγ and Veliparib for 24 hours as indicated.
Mol Cell

BRCA2-dependent maturation of nascent strands during DNA replication. [Abstract]

2026 Apr 16;86(8):1427-1440.e5. PMID: 41935526
Nat Chem Biol

The PARP1-EXD2 axis orchestrates R-loop resolution to safeguard genome stability. [Abstract]

2025 Jun 27. PMID: 40579572
Theranostics

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. [Abstract]

2020 Jul 25;10(21):9477-9494. PMID: 32863940
Adv Sci (Weinh)

Combining PIM-2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding. [Abstract]

2025 Aug;12(32):e02448. PMID: 40557764
Adv Sci (Weinh)

Disruption of ARID1B Recruitment to the Nuclear Pore Complex as a New Anticancer Therapeutic Strategy. [Abstract]

2025 Jul 16:e15585. PMID: 40671262

Veliparib purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 16:e15585. [Abstract]

Veliparib (0-100 μM; 72 h). Dose‐response curves for Veliparib after 72 h of treatment in MDA‐MB‐468 cells comparing empty vector control (Control) and ARID1B OE cells.
Cell Death Dis

Mitochondria-targeted oligomeric α-synuclein induces TOM40 degradation and mitochondrial dysfunction in Parkinson's disease and parkinsonism-dementia of Guam. [Abstract]

2024 Dec 18;15(12):914. PMID: 39695091
Cancer Genet

A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents. [Abstract]

2019 Nov:239:26-32. PMID: 31476665
Clin Cancer Res

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors. [Abstract]

2017 Feb 15;23(4):1001-1011. PMID: 27559053
Acta Pharmacol Sin

Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates. [Abstract]

2022 Apr;43(4):781-787. PMID: 34294887
J Transl Med

Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions. [Abstract]

2024 Nov 26;22(1):1062. PMID: 39587643
Oncogene

A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer. [Abstract]

2022 Sep;41(37):4271-4281. PMID: 35933519
Int J Biol Macromol

Exploring the stabilizing effect on the i-motif of neighboring structural motifs and drugs. [Abstract]

2023 Jul 1;242(Pt 2):124794. PMID: 37182626
Sci Signal

PARP1-mediated PARylation of TEAD4 stabilizes the YAP1-TEAD4 complex and promotes growth and immune evasion in breast cancer cells. [Abstract]

2025 Oct 21;18(909):eadx2532. PMID: 41118450
J Invest Dermatol

TRPV3-Activated PARP1/AIFM1/MIF Axis through Oxidative Stress Contributes to Atopic Dermatitis. [Abstract]

2024 Dec;144(12):2695-2705.e8. PMID: 38823435
Mol Cancer Ther

PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. [Abstract]

2019 Nov;18(11):2063-2073. PMID: 31413177
Ecotoxicol Environ Saf

PARP1 promotes NLRP3 activation via blocking TFEB-mediated autophagy in rotenone-induced neurodegeneration. [Abstract]

2023 Mar 1:252:114630. PMID: 36764072
Cells

New Insights into the Significance of PARP-1 Activation: Flow Cytometric Detection of Poly(ADP-Ribose) as a Marker of Bovine Intramammary Infection. [Abstract]

2021 Mar 9;10(3):599. PMID: 33803196
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Neoplasia

Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. [Abstract]

2025 May:63:101152. PMID: 40096771
Cancers (Basel)

Dual Targeting of CX3CR1 and PARP in Models of High-Grade Serous Ovarian Carcinoma. [Abstract]

2024 Nov 5;16(22):3728. PMID: 39594684
Cancers (Basel)

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors. [Abstract]

2024 Oct 10;16(20):3441. PMID: 39456536
Nanomaterials

Co-Encapsulation of Methylene Blue and PARP-Inhibitor into Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Enhanced PDT of Cancer. [Abstract]

2021 Jun 8;11(6):1514. PMID: 34201069
Neoplasia

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors. [Abstract]

2019 Jun;21(6):533-544. PMID: 31029033
Neoplasia

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. [Abstract]

2018 May;20(5):478-488. PMID: 29605721
Cell Signal

MYC amplification sensitizes TNBC to CHK1 inhibitors. [Abstract]

2025 Jul:131:111709. PMID: 40037423
Front Mol Biosci

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma. [Abstract]

2021 Apr 29:8:633344. PMID: 33996894
BMC Cancer

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. [Abstract]

2022 Mar 23;22(1):312. PMID: 35321693
Analyst

Determination of veliparib metabolic stability in the human liver microsomes using a hydrophilic interaction UPLC-MS/MS quantitative method: greenness assessment with an in silico study for ADME, DEREK alarms and metabolic lability. [Abstract]

2025 Dec 1;150(24):5501-5513. PMID: 41231074
Front Oncol

The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma. [Abstract]

2021 Jul 9:11:681441. PMID: 34307148
Biomed Res Int

ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines. [Abstract]

2023 Feb 6:2023:7891753. PMID: 36794257
FEBS Open Bio

Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP-ribose) glycohydrolase inhibitor. [Abstract]

2025 Dec 5. PMID: 41347713
EJNMMI Res

Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer. [Abstract]

2025 Apr 29;15(1):50. PMID: 40301197
J Chromatogr B Analyt Technol Biomed Life Sci

Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study. [Abstract]

2020 Oct 1:1154:122195. PMID: 32943176
Oncol Lett

DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines. [Abstract]

2025 Jan 7;29(3):128. PMID: 39822940
J Vet Med Sci

p53- and ROS-mediated AIF pathway involved in TGEV-induced apoptosis. [Abstract]

2018 Nov 23;80(11):1775-1781. PMID: 30249935

Veliparib purchased from MedChemExpress. Usage Cited in: J Vet Med Sci. 2018 Nov 23;80(11):1775-1781. [Abstract]

PK-15 cells are incubated with 20 μM ABT-888 for 1 hr and subsequently infected with transmissible gastroenteritis virus (TGEV) for 36 hr. Cells are collected and then subjected to Western blot analysis for PARP-1.
EANM Innovation

2026 May 19;3:100274.
bioRxiv

Design and Development of DNA Damage Chemical Inducers of Proximity (DD-CIP) for Targeted Cancer Therapy. [Abstract]

2025 Nov 4:2025.11.03.686423. PMID: 41278667
Research Square Preprint

2024 Nov 06.
Res Sq

Mitochondria-Targeted Oligomeric α-Synuclein Induces TOM40 Degradation and Mitochondrial Dysfunction in Parkinson's Disease and Parkinsonism-Dementia of Guam. [Abstract]

2024 Feb 21:rs.3.rs-3970470. PMID: 38464024
Research Square Preprint

2021 Feb.
Patent

US20200129476A1
Patent

US20200078369A1
Patent

US20180362972A1.
Patent

US20180263995A1.
Int J Curr Res Acad Rev

2017; 5(3): 53-64.
Electrostatics Joint Conference

2016 July.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 29 mg/mL (118.71 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0935 mL

20.4675 mL

40.9350 mL

5 mM

0.8187 mL

4.0935 mL

8.1870 mL

10 mM

0.4093 mL

2.0467 mL

4.0935 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[2]

PARP1 enzyme activity is measured by using a commercial assay kit with the exception that cell lysates containing wild-type PARP1 or PARP Y907 mutant are used in place of the PARP1 protein included with the kit. Total lysate (500 ng) is added to each reaction. The dose course of PARP inhibitor Veliparib (ABT-888) is from 0.01 to 1,000 μM. PARP enzyme activity of wild-type and mutants is determined after incubation with the substrate is measured using a plate reader^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[3]

Cell viability is quantified using the Cell Counting Kit-8 (CCK-8). This assay is based on Dojindo’s highly water-soluble tetrazolium salt. WST-8 is reduced by dehydrogenases in cells to give an orange, water-soluble formazan dye. The amount of the formazan dye generated by dehydrogenases in cells is directly proportional to the number of living cells. Briefly, exponentially growing HaCaT cells are seeded in 96-well plates at a density of 10,000 cells/well. 6 h or 24 h after exposure to sulfur mustard (SM) and the administration of Veliparib, the CCK-8 reagent is added^[3.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
MDA-MB-231 (0.5×10⁶), HCC1937 (2×10⁶) or MCF-7 (5×10⁶) cells are injected into the mammary fat pads of female nude (Swiss Nu/Nu) mice of 6-8 weeks of age. A1034 (0.5×10⁶) cells are injected into the mammary fat pads of female FVB/NJ mice of 6-8 weeks of age. H1993 (0.5×10⁶) cells are injected subcutaneously into the right flank of female nude (Swiss Nu/Nu) mice of 6-8 weeks of age. When the tumor volume reaches 50 mm³, PF-02341066 (5 mg/kg) and Foretinib (5 mg/kg), AG014699 (5 mg/kg) and Veliparib (25 mg/kg), dissolved in aqueous 50 mM sodium acetate, pH 4, are administered to mice five times per week as single agents or in combination for the number of days specified in the figure legend. Tumor is measured at the indicated time points, and tumor volume is calculated by the formula: π/6×length×width². For MDA-MB-231 and A1034 xenograft mouse models, mice are imaged before and after treatment using the IVIS Imaging System to assess tumor growth. Mice are injected with 100 μL of D-luciferin (15 mg/mL in PBS).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37. [Content Brief]

[2]. Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22(2):194-201. [Content Brief]

[3]. Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.0935 mL	20.4675 mL	40.9350 mL	102.3374 mL
	5 mM	0.8187 mL	4.0935 mL	8.1870 mL	20.4675 mL
	10 mM	0.4093 mL	2.0467 mL	4.0935 mL	10.2337 mL
	15 mM	0.2729 mL	1.3645 mL	2.7290 mL	6.8225 mL
	20 mM	0.2047 mL	1.0234 mL	2.0467 mL	5.1169 mL
	25 mM	0.1637 mL	0.8187 mL	1.6374 mL	4.0935 mL
	30 mM	0.1364 mL	0.6822 mL	1.3645 mL	3.4112 mL
	40 mM	0.1023 mL	0.5117 mL	1.0234 mL	2.5584 mL
	50 mM	0.0819 mL	0.4093 mL	0.8187 mL	2.0467 mL
	60 mM	0.0682 mL	0.3411 mL	0.6822 mL	1.7056 mL
	80 mM	0.0512 mL	0.2558 mL	0.5117 mL	1.2792 mL
	100 mM	0.0409 mL	0.2047 mL	0.4093 mL	1.0234 mL

Bioz

Keywords

Veliparib

51 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Veliparib

Olaparib

Talazoparib

Niraparib

Rucaparib

Saruparib

Pamiparib

Rucaparib phosphate

Etoposide

Oxaliplatin

Temozolomide

Cisplatin

Adavosertib

Publications Citing Use of MedChemExpress (MCE) Veliparib

Alle PARP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (51)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Veliparib

Olaparib

Talazoparib

Niraparib

Rucaparib

Saruparib

Pamiparib

Rucaparib phosphate

Etoposide

Oxaliplatin

Temozolomide

Cisplatin

Adavosertib

Publications Citing Use of MedChemExpress (MCE) Veliparib

Alle PARP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (51)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Veliparib Related Classifications

HY-10129 Related Classifications

Bioz